BioSpace News Archive

New COVID-19 estimates find that, among European nations, the peak daily death rate from the pandemic will occur during the third week of April, with the pandemic spreading from Southern Europe.

Phase 2/3 pivotal trial ongoing in patients up to 30 years of age undergoing surgery for pediatric central nervous system tumors

Cullgen Inc. announced that the company’s internal program to develop selective degraders that target key BRAF mutant proteins has been accepted for publication by the Journal of Medicinal Chemistry.

Phase I dose escalation completed for BT1718 — RP2D established and preliminary signs of anti-tumor activity observed, including one partial response - Dosing complete in second cohort of Phase I dose escalation for BT5528 — all doses administered in Phase I to date appear tolerable - Significant achievements in multiple partnered programs beyond oncology - Progress across pipeline continues despite uncertainties associated with coronav

Bristol Myers Squibb announced an expansion of its existing patient support programs to help eligible unemployed patients in the U.S. who have lost their health insurance due to the COVID-19 pandemic..

Swedish Orphan Biovitrum AB has released the company’s 2019 Annual and Sustainability Report.

Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced that the Canadian Patent Office has indicated its intent to grant the Company a patent for its invention titled “Methods and Compositions for Oral Administration of Proteins.”

Marketplace for scientific services named one of the 500 fastest-growing companies in North and South America

Presentation highlighted the potential of the company’s lead candidate, the anti-SEMA4D antibody pepinemab, to regulate glial cell activation and neurodegeneration in Alzheimer’s and Huntington’s disease

Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the appointment of Marc Schegerin, M.D., as chief financial officer and chief operating officer.